When I first started managing procurement for our network R&D lab, I assumed the cheapest instrument that met the spec sheet was the right call. Three purchase cycles later—and one $2,300 recalibration bill I hadn't planned for—I learned that "the price" and "the cost" are two different numbers.
Last spring, our HR coordinator asked me to help choose blood pressure monitors for the company wellness program. She expected me to grab a CVS blood pressure cuff and move on. Instead, I opened the same TCO spreadsheet I use when I spec an Anritsu signal analyzer. Comparing a $400 wearable to a $40 cuff felt like overkill at first. It wasn't. We ended up comparing them on three dimensions—total cost of ownership, validation, and the value of the data. The biggest trap was the same one I've hit repeatedly in the lab: assuming that "it measures something" means "it measures it correctly."
In the lab, we buy Anritsu almost exclusively. An Anritsu optical spectrum analyzer runs anywhere from $20,000 to $60,000-plus, depending on wavelength range and resolution bandwidth. A portable Anritsu signal analyzer—what our German team still calls the Signalzähler—is a similarly sized line item. Those numbers make finance flinch. But the real cost of ownership is in what happens after the purchase.
Every 12 to 24 months, that equipment goes back for calibration. We use an ISO/IEC 17025-accredited lab, and calibration alone runs about 3–5% of the purchase price. Skip it, and readings drift. In RF testing, a drifted reference means a failed site acceptance or—worse—a false pass that costs way more to uncover later. One quarter in 2023, our engineers spent about 14 hours chasing a "network issue" that turned out to be an uncalibrated instrument. At loaded labor rates, that was roughly $1,800 of wasted time. I've budgeted for calibration on every Anritsu purchase since then.
Now look at blood pressure monitors. A basic CVS blood pressure monitor is $25 to $60 (checked cvs.com, January 2025). The HeartGuide wearable that HR had been considering lists for around $499 (same date; verify current pricing). That's a 10x gap in sticker price. It looks indefensible in a procurement review until you stack the secondary costs.
The cheap cuff needs batteries. So does the wearable. The bigger cost is the follow-up visit. When an employee gets an odd reading on a $40 cuff, they don't re-test; they book a doctor's appointment. Depending on the plan, one or two copays erase the entire price gap between the cuff and the wearable.
The $40 cuff that produces questionable data ends up costing more than the $400 device that produces data you can trust. That's the same hidden-cost mechanism I found on a $60,000 spectrum analyzer.
In the lab, accuracy is printed on the datasheet, but it's only true under specific conditions. An Anritsu signal analyzer might quote ±0.5 dB amplitude accuracy, but that spec assumes a warm-up period, matched cables, and a recent calibration. The optical spectrum analyzer has a similar caveat around its wavelength reference. These are conditional claims, not absolute ones.
The clinical equivalent is a validation standard. For automated blood pressure monitors, the benchmark is AAMI/ESH/ISO 81060-2. A monitor passes it by matching a mercury sphygmomanometer across a broad range of arm sizes and pressures. It's the closest thing to a calibration sticker in consumer health.
Here's where my initial assumption failed. I assumed every cuff sold at a major retailer had been validated against something rigorous. Then I checked independent validation registries like Medaval, which track which models have actually been tested. The list had some surprising gaps: a number of cheap cuffs, including store-brand models, had never been validated at all.
The HeartGuide, by comparison, was validated per AAMI/ESH/ISO 81060-2. That's not accidental; the companies building this kind of wearable have deep experience in precision measurement, and they treat validation like calibration: an ongoing requirement, not a one-time marketing badge.
One more caveat, because it's a trap. A validation applies to the exact hardware and algorithm version that was tested. If the vendor tweaks the firmware or changes the cuff lining, the validation technically applies to the earlier version. That's like using a signal analyzer six months past its calibration sticker. It's probably fine. But "probably" isn't a specification. I've learned to check the model name, not just the brand name.
In the lab, I don't buy a signal analyzer for the screen. I buy it for the data. An optical spectrum analyzer gives me a trace I can save, compare, and trace back to a calibrated reference. A basic blood pressure cuff gives you a number that disappears when the screen turns off, unless someone writes it down.
This is the dimension where the comparison flips. A traditional cuff is like an analog power meter: it tells you the present state, but nothing about the trend. The HeartGuide stores thousands of timestamped readings, builds averages, and shows a pattern over weeks or months. For a wellness program, that trend is the entire point. You can spot white-coat hypertension (readings that spike only in clinical settings), morning surges, or the effect of a new medication. You can't see any of that from a single cuff reading.
One caveat, because it matters: data utility is not accuracy. A wearable doesn't produce a more accurate systolic number than a validated $60 cuff. Both rely on the same oscillometric principle that has been around since the 1970s. What the extra money buys is the system around the sensor—the battery, the app, the sync—that turns scattered readings into a dataset. For our screenings, that's the difference between "we held a health fair" and "we can see trends for 120 employees across 12 months."
Accounting for roughly $400,000 a year in test equipment spending over the past six years, my rule is simple: buy what fits the use case, and never skip the calibration. For blood pressure monitors, I'd split it into three scenarios:
Five years ago, my recommendation would have been simple: buy the cheapest cuff that gives consistent readings. That was the right call when cuffs were the only option. The wearable generation changed the calculus—not because the sensor changed overnight, but because the data around each reading did. The fundamentals haven't moved: a measurement is only worth paying for if it's validated and repeatable. What changed is the amount of context you can collect around each reading. That's what the extra money buys. And if you don't need it? Don't pay for it. That last part is the lesson procurement taught me: the most expensive purchase is the one that doesn't fit the use case.